Osteoporosis has been defined as the silent disease of the 21st century, becoming a public
health risk due to its severity, chronicity and progression and affecting mainly …

Osteoporosis refers to excessive bone loss as reflected by the deterioration of bone mass
and microarchitecture, which compromises bone strength. It is a complex multifactorial …

Postmenopausal osteoporosis (PMO) results from a reduction in bone mass and
microarchitectural deterioration in bone tissue due to estrogen deficiency, which may …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on developing the …

Since phosphorus is a component of hydroxyapatite, its prolonged deprivation affects bone
mineralization. Fibroblast growth factor 23 (FGF23) is essential for maintaining phosphate …

Abstract Summary The Saudi Osteoporosis Society (SOS) has updated its guidelines for the
diagnosis and management of osteoporosis in Saudi Arabia (SA), with emphasis on …

Osteocyte dysfunction exists at the nexus of diabetic skeletal disease. Therefore,
interventions targeting the RAGE signaling pathway, senescent cells, and those that inhibit …

Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on
bone formation. The monoclonal antibody against sclerostin has been approved as a novel …

Objective We investigated the clinical efficacy of anabolic agents compared with
bisphosphonates (BPs) for the incidence of new osteoporotic vertebral fracture (OVF) and …

Background Romosozumab is a novel monoclonal antibody that binds to sclerostin, and has
dual effects of increasing bone formation and decreasing bone resorption, giving it a unique …